Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817669 | 0.87 | HIF1A (0.53) | HIF1ALMNAMDM2MDM4 | |
| SCHEMBL14393899 | 0.78 | CYP2C19 (0.39) | HIF1AMMP1MMP2MMP8MMP13 | |
| SCHEMBL12967167 | 0.76 | KMT2A (0.39) | HTTLMNA | |
| SCHEMBL12376684 | 0.73 | MMP3 (0.39) | HIF1ALMNAPER2CRY1CRY2 | |
| SCHEMBL16316801 | 0.68 | ACACB (0.40) | — | |
| SCHEMBL12410297 | 0.67 | MMP3 (0.40) | LMNAPER2CRY1CRY2MMP1 | |
| SCHEMBL19021857 | 0.67 | HDAC4 (0.39) | — | |
| SCHEMBL26422098 | 0.67 | GAA (0.34) | HTTLMNA | |
| SCHEMBL16917911 | 0.65 | MEN1 (0.40) | MMP1MMP2MMP8MMP13 | |
| SCHEMBL14393900 | 0.65 | ALDH1A1 (0.40) | MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220028-A1 | MODULATING ANGIOGENESIS BY PROTEOMIMETICS OF VASCULAR ENDOTHELIAL GROWTH FACTOR | UNIVERSITY OF SOUTH FLORIDA | 2023-07-13 | — | — | US | disclosed |
| US-20230220028-A1 | MODULATING ANGIOGENESIS BY PROTEOMIMETICS OF VASCULAR ENDOTHELIAL GROWTH FACTOR | UNIVERSITY OF SOUTH FLORIDA | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220028-A1 | MODULATING ANGIOGENESIS BY PROTEOMIMETICS OF VASCULAR ENDOTHELIAL GROWTH FACTOR | VEGFA, FLT4, FLT1 | HIF1A 18/4885HTT 3551/4885LMNA 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.